eGFR slope as a surrogate endpoint for end-stage kidney disease in patients with diabetes and eGFR > 30 mL/min/1.73 m 2 in the J-DREAMS cohort.
Yuka SugawaraEiichiro KandaMitsuru OhsugiKohjiro UekiNaoki KashiharaMasaomi NangakuPublished in: Clinical and experimental nephrology (2023)
We found that changes in the eGFR slope were associated with ESKD risk in this population.